<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434744</url>
  </required_header>
  <id_info>
    <org_study_id>KD026-201</org_study_id>
    <nct_id>NCT02434744</nct_id>
  </id_info>
  <brief_title>Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety, tolerability and efficacy of the combination of KD026 and
      metformin compared to placebo and metformin on improving glycemic control in patients with
      type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess the safety, tolerability, and efficacy (as measured by a 0.5%-1.5% decrease of HbA1c) of different dosages and dosing regimens of a combination of KD026 and metformin compared to placebo and metformin when administered for 3 months to subjects with type 2 diabetes mellitus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes in fasting plasma glucose from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes in insulin from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HOMA-IR</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes in Homeostasis Model Assessment - Insulin Resistance (HOMA-IR) from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Weight</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in AUC</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess the 6-hour time curve (AUC) for post prandial triglycerides and glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipids</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes in total cholesterol, LDL-C, HDL-C, non-HDL-C, VLDL-C, and triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Pressure</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes, if any, in baseline blood pressure associated with metabolic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Waist Circumference</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes, if any, in baseline waist circumference associated with metabolic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Mass Index (BMI)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess changes, if any, in baseline measures of BMI associated with metabolic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasma Levels of KD026</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess plasma levels of KD026 in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Levels of Non-Esterified Free Fatty Acids</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess the change in serum levels of non-esterified free fatty acids from baseline to Week 12</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1 100 mg KD026 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 150 mg KD026 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg KD026 BID in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 200 mg KD026 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg KD026 BID in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 100 mg KD026 TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo Dose BID in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo Dose BID in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo Dose BID in combination with Metformin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo Dose TID in combination with Metformin for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD026</intervention_name>
    <description>Dosed in combination</description>
    <arm_group_label>Cohort 1 100 mg KD026 BID</arm_group_label>
    <arm_group_label>Cohort 2 150 mg KD026 BID</arm_group_label>
    <arm_group_label>Cohort 3 200 mg KD026 BID</arm_group_label>
    <arm_group_label>Cohort 4 100 mg KD026 TID</arm_group_label>
    <other_name>SLx-4090</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosed in combination</description>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Drug prescribed by each subject's prescribing physician</description>
    <arm_group_label>Cohort 1 100 mg KD026 BID</arm_group_label>
    <arm_group_label>Cohort 2 150 mg KD026 BID</arm_group_label>
    <arm_group_label>Cohort 3 200 mg KD026 BID</arm_group_label>
    <arm_group_label>Cohort 4 100 mg KD026 TID</arm_group_label>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes, with finger stick HbA1c ≥ 7.0% and ≤ 11.0% at screening visit,
             and HbA1c via venipuncture ≥ 7.0% and ≤ 11.0 % at the Qualification visit

          -  Have been on metformin for at least 12 weeks prior to screening visit and the
             metformin dose is not expected to change during the 4-week run-in period

          -  Have a BMI of ≥ 27 kg/m2 and ≤ 45 kg/m2

          -  Men, post-menopausal women (defined as not having a menstrual period for at least 1
             year), surgically sterile women (for at least 1 year), or women of childbearing
             potential with a negative pregnancy test within the last 24 hours

          -  Women of childbearing potential and men whose partners are of childbearing potential
             must agree to use two forms of accepted methods of contraception during the course of
             the study and for 1 month after their last dose of study drug. Effective birth control
             includes (a) IUD plus one barrier method; (b) on stable doses of hormonal
             contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus
             one barrier method; (c) 2 barrier methods. Effective barrier methods are male or
             female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to
             kill sperm); or (d) a vasectomized partner

        Exclusion Criteria:

          -  Have type 1 diabetes

          -  Taking antidiabetic medications other than or in addition to metformin

          -  Have fasting plasma glucose &gt; 270 mg/dL at screening visit

          -  Have a serum creatinine ≥1.7 mg/dL or glomerular filtration rate &lt;60 mL/min at
             screening visit

          -  Have a history of diabetic retinopathy

          -  Uncontrolled high blood pressure

          -  Have a history of chronic liver disease and/or alanine transaminase (ALT) or aspartate
             transaminase (AST) &gt;2.0 × the upper limit of normal (ULN) at screening visit.

          -  Have a history of a malignant cancer (other than basal cell, localized cervical, or
             squamous cell carcinoma of the skin that has been removed)

          -  Have a history or presence of gastrointestinal (GI) disease or major gastrointestinal
             surgery that, in the opinion of the investigator, could interfere with drug absorption

          -  Currently using any of prohibited medications that cannot be stopped

          -  Abuse alcohol (defined as an average weekly intake of greater than 21 units or an
             average daily intake of greater than 3 units [1 unit is equivalent to a half pint of
             beer, 1 serving of hard liquor, or one glass of wine]

          -  History or presence of drug abuse according to Diagnostic and Statistical Manual of
             Mental Disorders V (DSM-V) criteria within the 2 years prior to screening visit

          -  Have a 12-lead ECG at screening visit that, in the opinion of the investigator, have
             abnormalities that may compromise safety in this study, including a QTc(F) interval
             (QT interval data corrected using Fridericia's formula) of &gt; 450 msec

          -  Have a clinically significant abnormal laboratory result including thyroid-stimulating
             hormone (TSH) &gt;1.5 × ULN at screening visit

          -  Have a positive test for hepatitis B surface antigen (HBsAg), hepatitis C
             antibody/virus (HCV) or human immunodeficiency virus (HIV) antibodies at screening
             visit or a documented history of a positive result

          -  Pregnant or lactating woman

          -  Previously received KD026 (formerly named SLx-4090)

          -  Participated in a trial with any investigational drug within 4 weeks prior to
             screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infosphere Clinical Research, Inc</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Research of Florida, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <disposition_first_submitted>March 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 14, 2016</disposition_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

